You can Subscribe to our RSS FEED:
which delivers brain tumor news and additions
to the website via RSS.
Click HERE for details on RSS.
Displaying items 1 to 25 of about 5413
SonALAsense Achieves Significant Clinical, Growth and Funding Milestones Toward its Mission to Soundly Defeat Cancer
Share Your Experiences with GBM to Help Others
xCures and Novocure® partner to better understand quality of life in glioblastoma
Unintended effects of proton pump inhibitors (PPIs) in patients with glioblastoma (GBM): A double-edged sword
H3K27M-Altered Diffuse Midline Gliomas Among Adult Patients: A Systematic Review of Clinical Features and Survival Analysis
National Walk To End Brain Tumors - NJ
Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma
POSITIVE DATA FOR PAXALISIB IN TWO CHILDHOOD BRAIN CANCERS PRESENTED AT 20TH ISPNO ANNUAL MEETING
New method delivers life-saving drugs to the brain—using sound waves
GammaTile webinar posted to website!
Promising results from the GLORIA study presented at the ASCO 2022 meeting
Doses of widely-used acne treatment drug raise risk of brain tumours seven-fold
Resiliency of a perpetual optimist: neurosurgeon Dr. Linda Liau
Musella Foundation Awards Brain Tumor Research Grants!
Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical Program
Clinical Trials of Oncolytic Viruses in Glioblastoma
The safety profile of Tumor Treating Fields (TTFields) therapy in glioblastoma patients with ventriculoperitoneal shunts
Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry
PRESENTATION AT ASCO MEETING TO SHOW ENHANCED TUMOR BREAKDOWN BY COMBINING APG-157 WITH IMMUNO-ONCOLOGY DRUGS
FGA LEADS DIVERSE COALITION WITH LETTER SUPPORTING THE PROMISING PATHWAY ACT
Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma
Immunomic Therapeutics CEO expects meaningful test results for brain tumor drug
We respond to “promising” survival data from phase III trial of DCVax®-L
Our next webinar has been postponed!
Shortage of contrast dye forcing hospitals world-wide to ration, and delay procedures
Brain Tumor News Blast
Enter your email address to subscribe!
Copyright © 1993 - 2022 Musella Foundation- All Rights Reserved.
Website by LcsProductionDesign.com